Identification and evaluation of cross-protection efficiency of the conserved antigens of Salmonella Enteritidis.

IF 3.5
Vaccine Pub Date : 2025-08-30 Epub Date: 2025-08-14 DOI:10.1016/j.vaccine.2025.127622
Yuying Zhao, Guohui Li, Quan Li, Huoying Shi
{"title":"Identification and evaluation of cross-protection efficiency of the conserved antigens of Salmonella Enteritidis.","authors":"Yuying Zhao, Guohui Li, Quan Li, Huoying Shi","doi":"10.1016/j.vaccine.2025.127622","DOIUrl":null,"url":null,"abstract":"<p><p>Salmonella, a major foodborne zoonotic pathogen, threatens global poultry production and public health. While inactivated vaccines exhibit limited efficacy and live attenuated vaccines raise safety concerns due to risks of virulence reversion, subunit vaccines represent a safer and more targeted alternative. However, existing subunit vaccines against Salmonella provide limited cross-serotype protection. To address this challenge, OmpC, OmpD, OmpF (outer membrane proteins), SseB (a Type III secretory system secretory protein), and FliC (flagellin) were selected as five conserved antigens of Salmonella Enteritidis (S. enteritidis) for evaluation of their immune protective efficacy in this work. Our data showed that all antigens exhibited strong humoral and cell-mediated immune responses specific to each antigen, significantly reducing mortality and bacterial burdens following S. enteritidis challenge compared to infected controls. Notably, the SseB subunit vaccine demonstrated promising but serovar-dependent protection, inducing partial cross-reactive opsonophagocytic antibody (OPA) responses against Salmonella serovars. Protection experiments revealed divergent efficacy: 66.7 % survival against homologous S. enteritidis versus limited 33.3 % survival against heterologous S. typhimurium challenge. Both groups exhibited significantly reduced bacterial colonization and mitigated histopathological damage. These findings position SseB as a key candidate for serovar-specific subunit vaccines, laying the groundwork for multivalent approaches targeting conserved virulence machinery.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"62 ","pages":"127622"},"PeriodicalIF":3.5000,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.vaccine.2025.127622","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/14 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Salmonella, a major foodborne zoonotic pathogen, threatens global poultry production and public health. While inactivated vaccines exhibit limited efficacy and live attenuated vaccines raise safety concerns due to risks of virulence reversion, subunit vaccines represent a safer and more targeted alternative. However, existing subunit vaccines against Salmonella provide limited cross-serotype protection. To address this challenge, OmpC, OmpD, OmpF (outer membrane proteins), SseB (a Type III secretory system secretory protein), and FliC (flagellin) were selected as five conserved antigens of Salmonella Enteritidis (S. enteritidis) for evaluation of their immune protective efficacy in this work. Our data showed that all antigens exhibited strong humoral and cell-mediated immune responses specific to each antigen, significantly reducing mortality and bacterial burdens following S. enteritidis challenge compared to infected controls. Notably, the SseB subunit vaccine demonstrated promising but serovar-dependent protection, inducing partial cross-reactive opsonophagocytic antibody (OPA) responses against Salmonella serovars. Protection experiments revealed divergent efficacy: 66.7 % survival against homologous S. enteritidis versus limited 33.3 % survival against heterologous S. typhimurium challenge. Both groups exhibited significantly reduced bacterial colonization and mitigated histopathological damage. These findings position SseB as a key candidate for serovar-specific subunit vaccines, laying the groundwork for multivalent approaches targeting conserved virulence machinery.

肠炎沙门氏菌保守抗原交叉保护效能的鉴定与评价。
沙门氏菌是一种主要的食源性人畜共患病病原体,威胁着全球家禽生产和公共卫生。虽然灭活疫苗的效力有限,而减毒活疫苗由于毒力逆转的风险而引起安全问题,但亚单位疫苗是一种更安全、更有针对性的替代方案。然而,现有的针对沙门氏菌的亚单位疫苗提供有限的跨血清型保护。为了解决这一挑战,本研究选择了OmpC、OmpD、OmpF(外膜蛋白)、SseB (III型分泌系统分泌蛋白)和flc(鞭毛蛋白)作为肠炎沙门氏菌(S. Enteritidis)的5种保守抗原,对它们的免疫保护作用进行了评价。我们的数据显示,所有抗原对每种抗原都表现出强烈的体液和细胞介导的免疫反应,与感染对照相比,显著降低了肠炎沙门氏菌攻击后的死亡率和细菌负担。值得注意的是,SseB亚单位疫苗显示出有希望的但血清依赖的保护作用,诱导部分交叉反应性调节噬细胞抗体(OPA)应答沙门氏菌血清型。保护实验显示出不同的效果:对同源肠炎沙门氏菌的存活率为66.7%,而对异源伤寒沙门氏菌的存活率为33.3%。两组均表现出明显减少细菌定植和减轻组织病理学损伤。这些发现将SseB定位为血清特异性亚单位疫苗的关键候选物,为针对保守毒力机制的多价方法奠定了基础。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信